Theratechnologies inc.
TSX : TH

Theratechnologies inc.

June 19, 2009 09:05 ET

Theratechnologies Awarded Le Prix Sante by the Fondation Armand-Frappier

MONTREAL, CANADA--(Marketwire - June 19, 2009) - Theratechnologies (TSX:TH) is proud to announce that it was awarded the Fondation Armand-Frappier's Prix Sante 2009 at the 16th annual Fete Champetre held last evening on the campus of the INRS-Institut Armand-Frappier in Laval.

"It's an honour for Theratechnologies to receive this prestigious prize", said Yves Rosconi, the Company's President and Chief Executive Officer. "As genuine recognition by our peers, this prize pays tribute to the work and dedication of a team that was able to successfully complete a clinical program for tesamorelin, a molecule discovered in-house, file for marketing approval with the American regulatory authorities and join forces with an ideal partner for its commercialization in the United States", he added. "I would like to thank all of Theratechnologies' employees who, through their efforts, contributed to the achievement of our business-plan objectives, as well as our shareholders for their loyal support and patience", Mr. Rosconi concluded.

Awarded by the Fondation Armand-Frappier on the recommendation of its scientific committee, Le Prix Sante recognizes success by Quebec companies in the human health, animal health, environmental and agro-food fields. In order to qualify, companies must have conceived, developed and commercialized a scientific innovation, or be about to do so.

In 1998, Theratechnologies received Le Prix Emergence from the Fondation Armand-Frappier in recognition of its notable contribution to research and development in Quebec.

About the Fondation Armand-Frappier

The Fondation Armand-Frappier is a non-profit organization that encourages excellence in the training of the next generation of scientists and the advancement of health research in its areas of interest. Since its inception in 1978, the Fondation has distributed more than $8 million in the form of scholarships, research chairs, equipment purchases or contributions to scientific projects. The Fete Champetre, a true celebration of healthcare research, is the high point of its fund-raising activities and is considered a not-to-be-missed occasion by the business and life-science milieus.

About Theratechnologies

Theratechnologies (TSX:TH) is a Canadian biopharmaceutical company with core expertise in peptide-based therapeutics. Its most advanced compound, tesamorelin, is an analogue of the growth hormone releasing factor.

In 2008, Theratechnologies completed its Phase 3 clinical program evaluating tesamorelin in treating excess abdominal fat in HIV patients with lipodystrophy and signed a collaboration and licensing agreement with EMD Serono, Inc., for the commercialization of tesamorelin in the United States.

With a New Drug Application recently filed with the US authorities, Theratechnologies' growth strategy is firmly focused on the development of tesamorelin, in the United States and in other potential lipodystrophy markets, as well as through additional clinical programs.

Contact Information